Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Cancer treatments don't just target tumors — they also rewire the genetics of healthy cells. A new study in Nature Genetics found that chemotherapy and radiotherapy selectively boost cells with cancer-related mutations in normal esophageal tissue. Researchers say this could help explain treatment side effects and drug resistance, and may eventually lead to more targeted, less damaging therapies.
Cancer treatments don't just fight tumors — they're quietly reshaping the genetic makeup of healthy tissue too. A new study published in Nature Genetics by researchers from the Wellcome Sanger Institute, University of Cambridge, and University College London found that chemotherapy and radiotherapy selectively amplify cells carrying cancer-related mutations in the normal lining of the esophagus.
The team analyzed esophageal tissue from patients who received chemotherapy, chemoradiotherapy, or no treatment before surgery. They found that combined chemoradiotherapy dramatically increased the number of normal cells with mutations in TP53 (the so-called "guardian of the genome") and PPM1D. Chemotherapy alone boosted cells resistant to the drug 5-fluorouracil (5-FU) — a change that may protect healthy tissue from toxic side effects.
Key Takeaways:
Why it matters: Understanding how cancer treatments alter the genetics of healthy cells could unlock smarter, more personalized therapies — ones that destroy tumors while sparing normal tissue. It may also shed light on how cancers develop drug resistance over time.
